<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03071835</url>
  </required_header>
  <id_info>
    <org_study_id>20150899</org_study_id>
    <nct_id>NCT03071835</nct_id>
  </id_info>
  <brief_title>A Comparative Study of Subjects Past Their Final Follow-ON Visit</brief_title>
  <acronym>HYPERION</acronym>
  <official_title>A Comparative Study of Subjects tHree to Nine Years Past thEiR fInal Follow- ON Visit</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joshua M Hare</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Miami</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A comparative study to follow subjects who received stem cell therapies three, five, seven,
      and nine years after their follow-on visit. Subjects will be selected from a pool of previous
      Interdisciplinary Stem Cell Institute trial participants.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A comparative study to follow subjects who received stem cell therapies three, five, seven,
      and nine years after their follow-on visit. Subjects will be selected from a pool of previous
      Interdisciplinary Stem Cell Institute trial participants.

      Subjects will be followed during the study depending on the initial visit for this trial. The
      time point at which they are followed will depend on the subject's injection date in the
      previous trial. Depending on the subjects first treatment date (Day of injection) in the
      previous Interdisciplinary Stem Cell Institute (ISCI) cardiovascular clinical trial, subjects
      may be eligible for one to four study visits in this trial. Those who do not have a three,
      five or seven-year visit may receive informed consent at the year nine visit. Thus, subjects
      can be enrolled and consented at any visit if the previous eligible visit was missed.
    </textblock>
  </detailed_description>
  <overall_status>Enrolling by invitation</overall_status>
  <start_date type="Actual">June 23, 2016</start_date>
  <completion_date type="Anticipated">December 31, 2029</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2028</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Continued Improvement in subject's symptoms</measure>
    <time_frame>at 3, 5, 7 and 9 Years</time_frame>
    <description>Demonstrate change of subject's symptoms by assessing cardiac events over an extended period of time following participation in an ISCI cardiac trial where the subject received Investigational product.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Cardiac Function via Cardiac MRI</measure>
    <time_frame>at 3, 5, 7 and 9 Years</time_frame>
    <description>Evaluate Cardiac Function for changes, positive and negative via Cardiac MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cardiac Function via Cardiac CT</measure>
    <time_frame>at 3, 5, 7 and 9 Years</time_frame>
    <description>Evaluate Cardiac Function for changes, positive and negative via Cardiac CT</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Functional Capacity via the NYHA Class</measure>
    <time_frame>at 3, 5, 7 and 9 Years</time_frame>
    <description>Evaluate Functional Capacity via New York Heart Association (NYHA) Class Determination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate Functional Capacity via the Six Minute Walk Test</measure>
    <time_frame>at 3, 5, 7 and 9 Years</time_frame>
    <description>Evaluate Functional Capacity via the Six Minute Walk Test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate change in Quality of Life via the Minnesota Living with Heart Failure</measure>
    <time_frame>at 3, 5, 7 and 9 Years</time_frame>
    <description>Evaluate Quality Of Life Changes via Minnesota Living with Heart Failure (MLHF) Questionnaire</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluate change in Symptoms via cardiac events</measure>
    <time_frame>at 3, 5, 7 and 9 Years</time_frame>
    <description>Evaluate Progression or Regression of disease (i.e. death, Left Ventricular Assist Device (LVAD), heart transplant and/or continuous intravenous infusion therapy (dobutamine, Milrinone, etc)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Cardiomyopathies</condition>
  <condition>Heart Diseases</condition>
  <condition>Aging Frailty</condition>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Genetic testing will consist of collecting tissue and/or blood stored for future use.
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The population for this study will consist of subjects who previously participated at an
        ISCI Trial and who are able to consent to being followed past their Follow-On visit.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be 18 years of age and older

          -  Provide written informed consent

          -  Have been previously enrolled or currently participating in an investigator-initiated
             cardiovascular trial at ISCI (In cases where participants are currently enrolled in
             another clinical trial they are still able to participate concurrently in this trial).

        Exclusion Criteria:

          -  Have known, serious radiographic contrast allergy, which cannot be managed with
             premedication only if able to undergo MRI or CT.

          -  Have a history of drug or alcohol abuse within the past 24 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joshua M Hare, Md</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Miami</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ISCI / University of Miami Miller School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://isci.med.miami.edu</url>
    <description>Interdisciplinary Stem Cell Institute at the University of Miami Miller School of Medicine</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 13, 2017</study_first_submitted>
  <study_first_submitted_qc>March 1, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2017</study_first_posted>
  <last_update_submitted>February 15, 2018</last_update_submitted>
  <last_update_submitted_qc>February 15, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 19, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Miami</investigator_affiliation>
    <investigator_full_name>Joshua M Hare</investigator_full_name>
    <investigator_title>Louis Lemberg Professor of Medicine Director, Interdisciplinary Stem Cell Institute</investigator_title>
  </responsible_party>
  <keyword>Stem Cells</keyword>
  <keyword>Cardiovascular</keyword>
  <keyword>Quality of Life</keyword>
  <keyword>Cardiomyopathy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

